Luxdegalutamide

Luxdegalutamide
Clinical data
Other namesARV-766,JSB462
Routes of
administration		Oral
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (83S)-N-[(1r,3S)-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]-53-fluoro-6,82,86-trioxo-7-aza-4(1,4)-piperazina-2(1,4),8(3)-dipiperidina- 1(1),5(1,4)-dibenzenaoctaphane-14-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC45H54FN7O6
Molar mass807.968 g·mol−1
3D model (JSmol)
SMILES
  • CC1(C(C(C1OC2=CC(=C(C=C2)C#N)OC)(C)C)NC(=O)C3=CC=C(C=C3)N4CCC(CC4)CN5CCN(CC5)C6=CC(=C(C=C6)C(=O)N[C@H]7CCC(=O)NC7=O)F)C
InChI
  • InChI=InChI=1S/C45H54FN7O6/c1-44(2)42(45(3,4)43(44)59-33-12-8-30(26-47)37(25-33)58-5)50-39(55)29-6-9-31(10-7-29)52-18-16-28(17-19-52)27-51-20-22-53(23-21-51)32-11-13-34(35(46)24-32)40(56)48-36-14-15-38(54)49-41(36)57/h6-13,24-25,28,36,42-43H,14-23,27H2,1-5H3,(H,48,56)(H,50,55)(H,49,54,57)/t36-,42?,43?/m0/s1
  • Key:RDPPBRKNBBXPNZ-PJXMSJPKSA-N

Luxdegalutamide, also known as ARV-766 and JSB462, is an investigational oral androgen receptor (AR) degrader being developed by Arvinas for the treatment of metastatic castration-resistant prostate cancer (mCRPC).[1][2] It belongs to a class of drugs called proteolysis targeting chimeras (PROTACs), which are designed to selectively degrade specific proteins by hijacking the ubiquitin-proteasome system.[3] Luxdegalutamide is a second-generation PROTAC AR degrader that has demonstrated a broader efficacy profile and better tolerability compared to its predecessor, ARV-110, in clinical settings.[3] It has shown promise in overcoming resistance associated with certain AR mutations, including the L702H mutation, which is prevalent in up to 24% of treated mCRPC patients.[3] As of 2024, luxdegalutamide is being evaluated in phase I/II clinical trials for prostate cancer.[1][2][4]

  1. ^ a b "Luxdegalutamide - Arvinas". AdisInsight. Springer Nature Switzerland AG.
  2. ^ a b Rej RK, Allu SR, Roy J, Acharyya RK, Kiran IN, Addepalli Y, et al. (April 2024). "Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs". Pharmaceuticals. 17 (4): 494. doi:10.3390/ph17040494. PMC 11054475. PMID 38675453.
  3. ^ a b c Israel JS, Marcelin LM, Thomas C, Szczyrbová E, Fuessel S, Puhr M, et al. (July 2024). "Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium". Journal of Experimental & Clinical Cancer Research. 43 (1) 194. doi:10.1186/s13046-024-03125-5. PMC 11253403. PMID 39014480.
  4. ^ "Luxdegalutamide (ARV-766)". MedChemExpress. Retrieved 2025-01-22.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.